An 89Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor

Christian A. Mason, Susanne Kossatz, Lukas M. Carter, Giacomo Pirovano, Christian Brand, Navjot Guru, Carlos Pérez-Medina, Jason S. Lewis, Willem J.M. Mulder, Thomas Reiner (Corresponding author)

Onderzoeksoutput: Bijdrage aan tijdschriftTijdschriftartikelAcademicpeer review

2 Citaten (Scopus)


The immune function within the tumor microenvironment has become a prominent therapeutic target, with tumor-associated macrophages (TAMs) playing a critical role in immune suppression. We propose an 89Zr-labeled high-density lipoprotein (89Zr-HDL) nanotracer as a means of monitoring response to immunotherapy. Methods: Female MMTV-PyMT mice were treated with pexidartinib, a colony-stimulating factor 1 receptor (CSF1R) inhibitor, to reduce TAM density. The accumulation of 89Zr-HDL within the tumor was assessed using PET/CT imaging and autoradiography, whereas TAM burden was determined using immunofluorescence. Results: A significant reduction in 89Zr-HDL accumulation was observed in PET/CT images, with 2.9% ± 0.3% and 3.7% ± 0.2% injected dose/g for the pexidartinib- and vehicle-treated mice, respectively. This reduction was corroborated ex vivo and correlated with decreased TAM density. Conclusion: These results support the potential use of 89Zr-HDL nanoparticles as a PET tracer to quickly monitor the response to CSF1R inhibitors and other therapeutic strategies targeting TAMs.

Originele taal-2Engels
Pagina's (van-tot)433-436
Aantal pagina's4
TijdschriftJournal of Nuclear Medicine
Nummer van het tijdschrift3
StatusGepubliceerd - 1 mrt 2020

Vingerafdruk Duik in de onderzoeksthema's van 'An <sup>89</sup>Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor'. Samen vormen ze een unieke vingerafdruk.

  • Citeer dit

    Mason, C. A., Kossatz, S., Carter, L. M., Pirovano, G., Brand, C., Guru, N., Pérez-Medina, C., Lewis, J. S., Mulder, W. J. M., & Reiner, T. (2020). An 89Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor. Journal of Nuclear Medicine, 61(3), 433-436.